18th Annual Craig-Hallum Institutional Investor Conference

Shawn O’Connor, CEO

June 2, 2021
Safe Harbor Statement

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: continuing demand for the Company’s products, competitive factors, the Company’s ability to finance future growth, the Company’s ability to produce and market new products in a timely fashion, the Company’s ability to continue to attract and retain skilled personnel, and the Company’s ability to sustain or improve current levels of productivity. Further information regarding the Company’s risk factors is contained in the Company’s quarterly and annual reports filed with the Securities and Exchange Commission.
Our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives.
Company Overview

- **Industry-leading** provider of modeling and simulation solutions used by major pharmaceutical, biotech, chemical, consumer goods companies and regulatory agencies worldwide

- Innovative **software and services** to improve drug development from discovery to regulatory approval with supportive guidance from the FDA and ability to **lower cost** and time to market with a **higher likelihood of success**

- Solutions bridge **machine learning** and include pharmacokinetic-pharmacodynamic (**PKPD**), quantitative systems pharmacology & toxicology (**QSP/QST**), and physiologically based pharmacokinetic (**PBPK**), and Physiologically-Based Biopharmaceutics (**PBBM**) Modeling

- 10+ year track record of **consistent revenue and profitability** growth and successful M&A strategy
Our Value Proposition

Avg. cost of $1.4B and 10+ years to bring a drug to market \(^{1,2}\)

Our solutions allow customers to model and predict results of chemical and biological tests required in the R&D process to improve success rates at multiple points in the process:

– Computational AI models help scientists streamline and improve their processes
– Machine learning improves the models with ever-growing data sets
– Better informed clinical trial design and analyze clinical results
– Identify potential safety liabilities earlier, avoiding costly clinical failures
– Optimize efficacy and minimize toxicity by efficiently identifying dosing regimens

We’ve helped bring 40+ drugs to market and informed multiple development programs
We Improve Drug Discovery and Development
PBPK Software Solutions and AI Data Mining

- **GastroPlus®**
  - Simulating IV, oral, oral cavity, ocular, inhalation, skin and IM absorption, PBPK, PBBM, PD modeling and drug-drug interactions

- **ADMET Predictor®**
  - QSAR modeling enabling rapid prediction of 140+ ADMET properties Used for lead generation and optimization

- **DDDPlus™**
  - Mechanistic simulation engine for the in vitro dissolution predictions to accelerate and optimize drug formulation

- **MembranePlus™**
  - Predict how fast a drug candidate will pass across the important physiological membrane barriers (GI, BBB)

- **MedChem Designer™**
  - Chemical sketching tool with ADMET property predictions in connection with ADMET Predictor
PKPD Software Solutions

Monolix Suite®

Population PKPD Model to support dose regimen, risk exposure, clinical trial protocol design and analysis, drug label specifications and regulatory submission

Datxplore
Exploration and visualization of data

PKanalix
Non-compartmental and compartmental analysis

Mlxplore
Exploration and visualization of complex models

Monolix
Non-linear mixed effects (NME) modeling engine

Simulx
Clinical trial pharmacometrics simulations

Cloud-based data management application

KIWI™
Determine potential drug-induced liver injury hazard posed by individual drug candidates to support clinical trial optimization

Assess the potential for drug-induced kidney injury of drug candidates to support clinical trial optimization and clinical trial decision making

NASH model to predict efficacy for treatment modalities to support clinical trial optimization and clinical trial decision making

IPFsym (Idiopathic pulmonary fibrosis)

RADAsym (Acute radiation exposure)
Services Solutions

• 70+ scientific PhD experts provide insightful solutions to improve the productivity of science-based drug development

• Focusing on lead selection, pharmacology, ADMET and DMPK, dose regimen, efficacy and safety

• Capabilities include:
  – Population PKPD data assembly, modeling, simulation, analysis and regulatory submission
  – PBPK modeling and simulation
  – Liver and kidney safety modeling and analysis
  – QSP/QST modeling support and analysis
  – AI drug candidate prioritization
  – Global regulatory strategies
  – Regulatory and scientific writing
Janssen Case Study: Accelerating Regulatory Interactions

Virtual crossover trials to establish drug product specification after manufacturing changes

- Janssen changed the manufacturing process to improve efficiencies with scale-up techniques post approval
- FDA requested clinical study to confirm bioequivalence
- Built and validated the baseline model in GastroPlus® using existing clinical data from previously approved lots
- Assessed impact of formulation changes; defined drug product specifications
- Performed virtual trial simulations in different populations to confirm bioequivalence
- FDA accepted the GastroPlus® modeling results, clinical study request was waived

Virtual Bioequivalence Study Simulations

<table>
<thead>
<tr>
<th>API Lot</th>
<th>PE/NPE</th>
<th>Dose (mg)</th>
<th>AUC&lt;sub&gt;0-24&lt;/sub&gt; (ng·h/mL) [N=250]</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL) [N=250]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot 5</td>
<td>PE</td>
<td>50</td>
<td>4180</td>
<td>113.3 (110.7, 116.1)</td>
</tr>
<tr>
<td>Lot 1</td>
<td>NPE</td>
<td>50</td>
<td>3688</td>
<td>103.0 (100.9, 105.1)</td>
</tr>
<tr>
<td>Lot 5</td>
<td>PE</td>
<td>100</td>
<td>8242</td>
<td>102.2 (99.8, 104.6)</td>
</tr>
<tr>
<td>Lot 3</td>
<td>NPE</td>
<td>100</td>
<td>8001</td>
<td>101.9 (98.9, 104.1)</td>
</tr>
<tr>
<td>Lot 5</td>
<td>PE</td>
<td>300</td>
<td>24998</td>
<td>101.9 (98.9, 104.1)</td>
</tr>
<tr>
<td>Lot 2</td>
<td>NPE</td>
<td>300</td>
<td>24460</td>
<td>101.9 (98.9, 104.1)</td>
</tr>
<tr>
<td>Lot 5</td>
<td>PE</td>
<td>100</td>
<td>8242</td>
<td>98.2 (96.2, 100.2)</td>
</tr>
<tr>
<td>Lot 4</td>
<td>NPE</td>
<td>100</td>
<td>8395</td>
<td>101.9 (98.9, 104.1)</td>
</tr>
<tr>
<td>Lot 5</td>
<td>PE</td>
<td>300</td>
<td>24998</td>
<td>101.9 (98.9, 104.1)</td>
</tr>
<tr>
<td>Lot 4</td>
<td>NPE</td>
<td>300</td>
<td>24525</td>
<td>101.9 (98.9, 104.1)</td>
</tr>
</tbody>
</table>

API: active pharmaceutical ingredient; AUC<sub>0-24</sub>: area under the plasma concentration-time curve from time 0 to 24 hours; GM: geometric mean; GMR: geometric mean ratio; NPE: non-particle-engineered; PE: particle-engineered; C<sub>max</sub>: maximum observed plasma concentration; CI: confidence interval.
Client Case Study: Strategic Use of Modeling & Simulation

In Silico Methods Improve the Probability of Phase 3 Success

- Client with novel antibody for prophylactic use in competitive migraine market had Phase 3 development plan with predicted probability of success of <15%
- Iteratively developed model throughout Phase 1 & Phase 2
- Implemented model-based clinical trial simulation strategy to improve Phase 3 design
- Phase 3 trials demonstrated safety and efficacy in preventing migraine
- Months of development time and millions of dollars saved by avoiding failed Phase 3 trials, also reduced time to approval and market
- Reduced unnecessary burden on patients by evaluating multiple alternatives *in silico* before running trials
Growth Drivers

- Increasing acceptance of modeling and simulation by FDA and drug industry
- High customer satisfaction with ~95% software contract renewal rate (by fees)
- Recently improved and expanded sales infrastructure
- Increasing opportunities for product and service cross-selling
- Steadily increasing industry R&D spend
- Synergistic acquisitions

19%+ Revenue CAGR
Consistent Revenue Growth
FY21 YTD (through Q2)

(3in millions)

<table>
<thead>
<tr>
<th></th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>FY20</th>
<th>FY21 YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software</td>
<td>$14.9</td>
<td>$17.0</td>
<td>$18.5</td>
<td>$21.6</td>
<td>$14.0</td>
</tr>
<tr>
<td>Services</td>
<td>$9.2</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$20.0</td>
<td>$9.8</td>
</tr>
<tr>
<td>Total</td>
<td>$24.1</td>
<td>$29.7</td>
<td>$34.0</td>
<td>$41.6</td>
<td>$23.8</td>
</tr>
</tbody>
</table>

19% CAGR
22% Growth

FY21 YTD (through Q2)
Software and Services Performance
FY21 YTD (through Q2)

Software Products % of Software Revenues
- GastroPlus: 56%
- Monolix Suite: 19%
- ADMET Predictor: 17%
- Other Software: 8%

Services Offerings % of Services Revenues
- PKPD: 52%
- QSP/QST: 29%
- PBPK: 19%

59% of Total Revenue
41% of Total Revenue
Global Customer Base

Revenue by Region
FY21 YTD (through Q2)

Americas: 66%
EMEA: 23%
Asia Pacific: 11%
Strategic Opportunities for Expansion and Growth

• Expand product offerings through opportunistic acquisitions
  – Fill gaps in the current product offerings
  – Focus on immediately or near-term accretive opportunities
  – Fragmented industry amenable to consolidation
• Further expand global sales reach
  – Increase sales effort to drive new customer growth in U.S., Europe and Asia
  – Expand client base in the small and mid-sized biotechnology space
  – Focus on cross-selling efforts to increase average revenue per customer
• Increase R&D investment to enhance existing models and develop new tools to broaden product offerings
FY21 Q2 YTD Performance & FY21 Full Year Guidance

- **Total Revenue Growth**
  - YTD performance: 21% y/y growth
  - Full-year guidance range: 15-20% y/y organic growth plus 3-5% from Lixoft

- **Software Revenue Growth**
  - YTD performance: 40% y/y growth
  - Full-year guidance range: 20-25% y/y growth

- **Services Revenue Growth**
  - YTD performance: 1% y/y growth
  - Full-year guidance range: 25-30% y/y growth

- **YTD Profitability**
  - Gross margin was 78%, up from 73% the prior fiscal year period
  - Net income increased 35% y/y to $5.7 million
  - Diluted earnings per share increased 17% y/y to $0.27 per share

- **M&A Efforts**
  - Continuing to explore opportunities and acquisitions that would be incremental to revenue growth targets above
Investment Highlights

✓ Leading provider of innovative modeling and simulation software and consulting services focused on pharmaceutical and biotechnology companies
  ➢ Solutions from early discovery through regulatory approval
✓ Pure play in the *in silico* drug discovery space
✓ Growing acceptance of technology by regulators and industry with supportive guidance issued by the FDA
✓ Products have the potential to reduce drug development costs and time while improving success rates
✓ Steady growth in pharmaceutical industry R&D expenditures provides expanding target market
  ➢ ~$170B in 2020 growing around 3% per year\(^3\)
✓ 10+ year track record of consistent revenue and profitability growth
  ➢ Recent revenue CAGR of 20%+
## Financial Summary and Selected Financial Information

<table>
<thead>
<tr>
<th>Nasdaq Global Select Market</th>
<th>SLP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 Cash and short-term investments</td>
<td>$118M</td>
</tr>
<tr>
<td>Q2 Borrowed Debt Outstanding</td>
<td>$0</td>
</tr>
<tr>
<td>Market Capitalization (a/o 5/25/21)</td>
<td>$1.0B</td>
</tr>
<tr>
<td>Q2 Fully Diluted Shares Outstanding</td>
<td>20.8M</td>
</tr>
<tr>
<td>30-Day Avg. Daily Trading Volume (a/o 5/12/21)</td>
<td>~206K</td>
</tr>
</tbody>
</table>
# Covering Analysts

<table>
<thead>
<tr>
<th>Bank</th>
<th>Analyst</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig-Hallum</td>
<td>Matt G. Hewitt</td>
</tr>
<tr>
<td>Oppenheimer &amp; Co.</td>
<td>Francois Brisebois</td>
</tr>
<tr>
<td>Raymond James</td>
<td>Dane Leone</td>
</tr>
</tbody>
</table>
Thank you!
References

